Afatinib Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02183883Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
NCT02716311Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer